THRB and metabolic dysfunction-associated steatohepatitis: Resmetirom (MGL-3196) is found to be the most promising TRβ-selective agonist for NASH treatment with potential to reduce plasma LDL-C and triglyceride concentrations accompanied by cardio-protective potential